BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18299491)

  • 21. Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials.
    Perez MV; Wang PJ; Larson JC; Virnig BA; Cochrane B; Curb JD; Klein L; Manson JE; Martin LW; Robinson J; Wassertheil-Smoller S; Stefanick ML
    Circ Arrhythm Electrophysiol; 2012 Dec; 5(6):1108-16. PubMed ID: 23169946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen plus progestin and risk of venous thrombosis.
    Cushman M; Kuller LH; Prentice R; Rodabough RJ; Psaty BM; Stafford RS; Sidney S; Rosendaal FR;
    JAMA; 2004 Oct; 292(13):1573-80. PubMed ID: 15467059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects.
    Zhao S; Chlebowski RT; Anderson GL; Kuller LH; Manson JE; Gass M; Patterson R; Rohan TE; Lane DS; Beresford SA; Lavasani S; Rossouw JE; Prentice RL
    Breast Cancer Res; 2014 Mar; 16(2):R30. PubMed ID: 24670297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
    Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
    Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
    Chlebowski RT; Anderson GL; Sarto GE; Haque R; Runowicz CD; Aragaki AK; Thomson CA; Howard BV; Wactawski-Wende J; Chen C; Rohan TE; Simon MS; Reed SD; Manson JE
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26668177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk.
    Byrne C; Ursin G; Martin CF; Peck JD; Cole EB; Zeng D; Kim E; Yaffe MD; Boyd NF; Heiss G; McTiernan A; Chlebowski RT; Lane DS; Manson JE; Wactawski-Wende J; Pisano ED
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.
    Manson JE; Aragaki AK; Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Chlebowski RT; Howard BV; Thomson CA; Margolis KL; Lewis CE; Stefanick ML; Jackson RD; Johnson KC; Martin LW; Shumaker SA; Espeland MA; Wactawski-Wende J;
    JAMA; 2017 Sep; 318(10):927-938. PubMed ID: 28898378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.
    Prentice RL; Manson JE; Langer RD; Anderson GL; Pettinger M; Jackson RD; Johnson KC; Kuller LH; Lane DS; Wactawski-Wende J; Brzyski R; Allison M; Ockene J; Sarto G; Rossouw JE
    Am J Epidemiol; 2009 Jul; 170(1):12-23. PubMed ID: 19468079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.
    Barnabei VM; Cochrane BB; Aragaki AK; Nygaard I; Williams RS; McGovern PG; Young RL; Wells EC; O'Sullivan MJ; Chen B; Schenken R; Johnson SR;
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1063-73. PubMed ID: 15863546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmenopausal hormone therapy and mammographic breast density.
    Marchesoni D; Driul L; Ianni A; Fabiani G; Della Martina M; Zuiani C; Bazzocchi M
    Maturitas; 2006 Jan; 53(1):59-64. PubMed ID: 15939560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
    Gambacciani M; Ciaponi M; Cappagli B; Genazzani AR
    Am J Obstet Gynecol; 2001 Nov; 185(5):1180-5. PubMed ID: 11717654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial.
    Lindenfeld EA; Langer RD
    Obstet Gynecol; 2002 Nov; 100(5 Pt 1):853-63. PubMed ID: 12423841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen plus progestin and risk of benign proliferative breast disease.
    Rohan TE; Negassa A; Chlebowski RT; Lasser NL; McTiernan A; Schenken RS; Ginsberg M; Wassertheil-Smoller S; Page DL
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2337-43. PubMed ID: 18725513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view.
    Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F
    J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
    Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
    Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?
    Falk RT; Manson JE; Barnabei VM; Anderson GL; Brinton LA; Rohan TE; Cauley JA; Chen C; Coburn SB; Pfeiffer RM; Reding KW; Sarto GE; Wentzensen N; Chlebowski RT; Xu X; Trabert B
    Int J Cancer; 2019 Feb; 144(4):730-740. PubMed ID: 30183089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.
    Wassertheil-Smoller S; Hendrix SL; Limacher M; Heiss G; Kooperberg C; Baird A; Kotchen T; Curb JD; Black H; Rossouw JE; Aragaki A; Safford M; Stein E; Laowattana S; Mysiw WJ;
    JAMA; 2003 May; 289(20):2673-84. PubMed ID: 12771114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial.
    Nevitt MC; Felson DT; Williams EN; Grady D
    Arthritis Rheum; 2001 Apr; 44(4):811-8. PubMed ID: 11315920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.